CD19 and acute lymphoblastic leukemia: Blinatumomab, a bispecific antibody targeting both CD19 and CD3, has been recently approved by both the EMA and FDA for treating children with refractory or relapsing forms of CD19-positive B-precursor acute lymphoblastic leukemia.